Cargando…
Treatment Assessment of pNET and NELM after Everolimus by Quantitative MRI Parameters
Assessment of treatment response to targeted therapies such as everolimus is difficult, especially in slow-growing tumors such as NETs. In this retrospective study, 17 patients with pancreatic neuroendocrine tumors (pNETs) and hepatic metastases (NELMs) (42 target lesions) who received everolimus we...
Autores principales: | Ingenerf, Maria, Kiesl, Sophia, Winkelmann, Michael, Auernhammer, Christoph J., Rübenthaler, Johannes, Grawe, Freba, Fabritius, Matthias P., Ricke, Jens, Schmid-Tannwald, Christine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599819/ https://www.ncbi.nlm.nih.gov/pubmed/36289880 http://dx.doi.org/10.3390/biomedicines10102618 |
Ejemplares similares
-
(68)Ga-DOTATATE PET/CT and MRI with Diffusion-Weighted Imaging (DWI) in Short- and Long-Term Assessment of Tumor Response of Neuroendocrine Liver Metastases (NELM) Following Transarterial Radioembolization (TARE)
por: Ingenerf, Maria, et al.
Publicado: (2021) -
Diagnostic performance of PET/CT in the detection of liver metastases in well-differentiated NETs
por: Grawe, Freba, et al.
Publicado: (2023) -
Quantitative SSTR-PET/CT for predicting response and survival outcomes in patients with pancreatic neuroendocrine tumors receiving CAPTEM
por: Ingenerf, Maria, et al.
Publicado: (2023) -
Diagnostic accuracy of SSR-PET/CT compared to histopathology in the identification of liver metastases from well-differentiated neuroendocrine tumors
por: Fabritius, M. P., et al.
Publicado: (2023) -
Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients
por: Grawe, Freba, et al.
Publicado: (2023)